Premium
Agomelatine: first melatonergic agonist for depression
Author(s) -
Deakin Bill
Publication year - 2009
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.554
Subject(s) - agomelatine , medicine , agonist , antidepressant , depression (economics) , melatonin , pharmacology , psychiatry , receptor , neuroscience , psychology , macroeconomics , economics , anxiety
Agomelatine (Valdoxan) is a new antidepressant with unique melatonin receptor agonist activity. In our New products review, Professor Bill Deakin presents the clinical data relating to its efficacy and safety, and describes its place in the treatment of depression. Copyright © 2009 Wiley Interface Ltd.